Ameritas Investment Partners’s Ovid Therapeutics OVID Stock Holding History

Ameritas Investment Partners’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,924	Closed	-$1.54K	–	3304
2025 Q1	$1.54K	Hold	4,924	–	–	﹤0.01%	3086
2024 Q4	$4.6K	Hold	4,924	–	–	﹤0.01%	3038
2024 Q3	$5.81K	Hold	4,924	–	–	﹤0.01%	3022
2024 Q2	$3.79K	Hold	4,924	–	–	﹤0.01%	3058
2024 Q1	$15K	Hold	4,924	–	–	﹤0.01%	2676
2023 Q4	$15.9K	Hold	4,924	–	–	﹤0.01%	2689
2023 Q3	$18.9K	Hold	4,924	–	–	﹤0.01%	2566
2023 Q2	$16.2K	Buy	+4,924	New	+$16.7K	﹤0.01%	2674
2021 Q2	–	Sell	-3,782	Closed	-$15K	–	3183
2021 Q1	$15K	Hold	3,782	–	–	﹤0.01%	2683
2020 Q4	$9K	Hold	3,782	–	–	﹤0.01%	2833
2020 Q3	$22K	Hold	3,782	–	–	﹤0.01%	2327
2020 Q2	$28K	Buy	+3,782	New	+$17.7K	﹤0.01%	2168
2019 Q2	–	Sell	-443	Closed	-$1K	–	3095
2019 Q1	$1K	Hold	443	–	–	﹤0.01%	2966
2018 Q4	$1K	Hold	443	–	–	﹤0.01%	2981
2018 Q3	$3K	Hold	443	–	–	﹤0.01%	2993
2018 Q2	$3K	Hold	443	–	–	﹤0.01%	2972
2018 Q1	$3K	Hold	443	–	–	﹤0.01%	2907
2017 Q4	$4K	Hold	443	–	–	﹤0.01%	2895
2017 Q3	$4K	Hold	443	–	–	﹤0.01%	2940
2017 Q2	$5K	Buy	+443	New	+$5.78K	﹤0.01%	2933

Other funds holding OVID

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Ameritas Investment Partners's OVID Position: Q2 2025 in Review

Ameritas Investment Partners sold out of Ovid Therapeutics (OVID) in Q2 2025, closing a stake of 4,924 shares — an estimated $1.54K sold.

Ameritas Investment Partners first reported a position in OVID in Q2 2017 and held it in 20 quarters. The position peaked at $28K in Q2 2020. 71 funds tracked by Wall St. Rank hold OVID as of Q2 2025.

Ameritas Investment Partners reported no remaining Ovid Therapeutics position as of Q2 2025 after selling out during the quarter.
Ameritas Investment Partners sold 4,924 Ovid Therapeutics shares in Q2 2025, an estimated $1.54K.
Ameritas Investment Partners first reported a position in Ovid Therapeutics in Q2 2017 and held it in 20 quarters.
Ameritas Investment Partners's Ovid Therapeutics position peaked at $28K in Q2 2020.
71 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2025.

Based on Ameritas Investment Partners's 13F filing for Q2 2025, filed 12 Aug 2025.